Alar Pharmaceuticals

6785.TWO

5.57 USD

-0.16

-2.79%

Overview

Last close

5.57 usd

Market cap

372.03M usd

52 week high

14.60 usd

52 week low

3.77 usd

Target price

N/A usd

Valuation

P/E

25.137

Forward P/E

N/A

Price/Sales

26.1209

Price/Book Value

4.9383

Enterprise Value

306.14M usd

EV/Revenue

12897.4675

EV/EBITDA

21.9707

Key financials

Revenue TTM

14.64M usd

Gross Profit TTM

N/A usd

EBITDA TTM

11.99M usd

Earnings per Share

0.23 usd

Dividend

0.05 usd

Total assets

2.55B usd

Net debt

-676.69M usd

About

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.